Biotech is moving beyond the ‘disaster’ of the past 2 years, says Michael Yee

As Nasdaq’s biotechnology exchange-traded fund (IBB) percolates higher on the year, some analysts see a struggling sector finally dragging itself out of the weeds. “Obviously, the last two years were in some ways a disaster for biotech,” said Michael...